DANONE (BSN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSN - FR0000120644 - Common Stock
75.08 EUR
+0.56 (+0.75%)
Taking everything into account, BSN scores 5 out of 10 in our fundamental rating. BSN was compared to 60 industry peers in the Food Products industry. While BSN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
BSN had positive earnings in the past year.
BSN had a positive operating cash flow in the past year.
BSN had positive earnings in each of the past 5 years.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.20%, BSN is in the better half of the industry, outperforming 65.00% of the companies in the same industry.
BSN has a better Return On Equity (11.59%) than 66.67% of its industry peers.
BSN has a Return On Invested Capital of 6.83%. This is in the better half of the industry: BSN outperforms 66.67% of its industry peers.
BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 6.36%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN's Profit Margin of 6.72% is fine compared to the rest of the industry. BSN outperforms 75.00% of its industry peers.
BSN's Profit Margin has been stable in the last couple of years.
BSN has a better Operating Margin (13.25%) than 78.33% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
BSN's Gross Margin of 50.47% is fine compared to the rest of the industry. BSN outperforms 78.33% of its industry peers.
BSN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BSN has been increased compared to 1 year ago.
Compared to 5 years ago, BSN has less shares outstanding
BSN has a better debt/assets ratio than last year.
2.2 Solvency
BSN has an Altman-Z score of 2.51. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.51, BSN is in the better half of the industry, outperforming 63.33% of the companies in the same industry.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 5.07, BSN is doing good in the industry, outperforming 71.67% of the companies in the same industry.
BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.83, BSN is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.51 |
ROIC/WACC1.06
WACC6.42%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.95, BSN is doing worse than 73.33% of the companies in the same industry.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio (0.78) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
BSN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.54%.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
The Earnings Per Share is expected to grow by 6.39% on average over the next years.
BSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.16% yearly.
EPS Next Y7.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
EPS Next 5Y6.39%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y3.16%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 20.07, which indicates a rather expensive current valuation of BSN.
The rest of the industry has a similar Price/Earnings ratio as BSN.
Compared to an average S&P500 Price/Earnings ratio of 27.17, BSN is valued a bit cheaper.
A Price/Forward Earnings ratio of 17.93 indicates a rather expensive valuation of BSN.
Based on the Price/Forward Earnings ratio, BSN is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 23.79. BSN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.07 | ||
| Fwd PE | 17.93 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.83 | ||
| EV/EBITDA | 10.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.51
PEG (5Y)N/A
EPS Next 2Y7.4%
EPS Next 3Y7.7%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.80%, BSN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.24, BSN pays a bit more dividend than its industry peers.
BSN's Dividend Yield is a higher than the S&P500 average which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
FRA:BSN (1/6/2026, 7:00:00 PM)
75.08
+0.56 (+0.75%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap51.16B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target80.85 (7.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.05%
PT rev (3m)2.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.07 | ||
| Fwd PE | 17.93 | ||
| P/S | 1.87 | ||
| P/FCF | 17.83 | ||
| P/OCF | 13.3 | ||
| P/B | 3.23 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.79 |
EPS(TTM)3.74
EY4.98%
EPS(NY)4.19
Fwd EY5.58%
FCF(TTM)4.21
FCFY5.61%
OCF(TTM)5.64
OCFY7.52%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.51
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.51 |
F-Score8
WACC6.42%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y3.16%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.93%
EBIT Next 3Y14.73%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the earnings growth outlook for DANONE?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.99% in the next year.
Is the dividend of DANONE sustainable?
The dividend rating of DANONE (BSN.DE) is 5 / 10 and the dividend payout ratio is 74.99%.